Axelia Oncology
- Biotech or pharma, therapeutic R&D
AXA042 is a synthetic TLR2/6 specific agonist for innate immune stimulation in PhI trials. Data show clear clinical benefit in solid tumours. We are seeking discussions with potential partners to understand their interests.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}